{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"133"},{"groupId":"OG002","value":"145"}],"units":"Participants"}],"description":"Overall response defined as a best overall response of complete response (CR), very good partial response (VGPR) or partial response (PR), assessed by the Investigator using the IMWG uniform response criteria.\n\nCR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% plasma cells in bone marrow.\n\nVGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours (h).\n\nPR requires 1 of the following:\n\n* ≥50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \\<200 mg/24 h, or\n* If M-protein not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels, or\n* If FLC not measurable, a ≥ 50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%.\n\nIf present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.","groups":[{"description":"Participants received bortezomib (Velcade) 1.3 mg/m\\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG000","title":"Bortezomib and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG001","title":"Bortezomib, Thalidomide, and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG002","title":"Bortezomib, Melphalan and Prednisone"}],"paramType":"NUMBER","populationDescription":"Response-Evaluable population, defined as all participants who received at least 1 dose of any study drug, have measurable disease at baseline, and have at least one post-baseline M-protein measurement.","reportingStatus":"POSTED","timeFrame":"Response assessed every other cycle for up to 13 cycles (49 weeks).","title":"Percentage of Participants With an Overall Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}